Stoke Therapeutics (NASDAQ:STOK) Shares Up 6.9% – Time to Buy?

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) were up 6.9% on Wednesday . The company traded as high as $10.00 and last traded at $10.50. Approximately 13,795 shares were traded during trading, a decline of 98% from the average daily volume of 822,257 shares. The stock had previously closed at $9.82.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Leerink Partners began coverage on shares of Stoke Therapeutics in a research note on Monday, October 14th. They issued an “outperform” rating and a $18.00 price target for the company. Chardan Capital assumed coverage on shares of Stoke Therapeutics in a research report on Friday, December 20th. They set a “buy” rating and a $24.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $35.00 target price on shares of Stoke Therapeutics in a report on Wednesday, January 8th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, January 8th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $21.29.

Stoke Therapeutics Price Performance

The company has a fifty day moving average price of $11.08 and a two-hundred day moving average price of $12.72.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.05. The company had revenue of $4.89 million during the quarter, compared to analysts’ expectations of $3.46 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. As a group, analysts anticipate that Stoke Therapeutics, Inc. will post -2.03 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Stoke Therapeutics news, insider Barry Ticho sold 10,000 shares of the company’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $12.07, for a total transaction of $120,700.00. Following the completion of the transaction, the insider now owns 51,277 shares in the company, valued at approximately $618,913.39. This represents a 16.32 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Edward M. Md Kaye sold 6,170 shares of the business’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $12.78, for a total transaction of $78,852.60. Following the transaction, the chief executive officer now owns 68,671 shares in the company, valued at approximately $877,615.38. This trade represents a 8.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 62,849 shares of company stock valued at $809,421. Insiders own 11.30% of the company’s stock.

Institutional Investors Weigh In On Stoke Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. RTW Investments LP boosted its stake in shares of Stoke Therapeutics by 10.1% in the third quarter. RTW Investments LP now owns 4,652,285 shares of the company’s stock valued at $57,177,000 after buying an additional 427,447 shares in the last quarter. State Street Corp lifted its holdings in Stoke Therapeutics by 8.6% in the third quarter. State Street Corp now owns 1,728,888 shares of the company’s stock valued at $21,248,000 after acquiring an additional 137,145 shares during the period. Healthcare of Ontario Pension Plan Trust Fund boosted its position in shares of Stoke Therapeutics by 426.1% during the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company’s stock worth $18,741,000 after purchasing an additional 1,123,500 shares in the last quarter. Assenagon Asset Management S.A. grew its stake in shares of Stoke Therapeutics by 2.9% during the 4th quarter. Assenagon Asset Management S.A. now owns 1,350,925 shares of the company’s stock worth $14,901,000 after purchasing an additional 38,446 shares during the period. Finally, Geode Capital Management LLC increased its holdings in shares of Stoke Therapeutics by 9.7% in the 3rd quarter. Geode Capital Management LLC now owns 870,831 shares of the company’s stock valued at $10,705,000 after purchasing an additional 76,661 shares in the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.